Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVOR PERCENT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619053998
CMS profile
209399
Location
PORT CHARLOTTE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$9,139.38

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVOR PERCENT

NPI 1619053998 · CMS profile ID 209399

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PORT CHARLOTTE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619053998?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVOR PERCENT, NPI 1619053998, CMS profile ID 209399. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619053998?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). IVOR PERCENT, NPI 1619053998, CMS profile ID 209399. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619053998?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
IVOR PERCENT, NPI 1619053998, CMS profile ID 209399, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1619053998?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $9,139.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim International GmbH $505.5506/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822296047 CMS
GENZYME CORPORATION $15.3706/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843587427 CMS
Dova Pharmaceuticals $15.2106/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849745803 CMS
Exelixis Inc. $13.3306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838868769 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845877819 CMS
GENZYME CORPORATION $19.0705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843587431 CMS
JAZZ PHARMACEUTICALS INC. $14.0005/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845589297 CMS
E.R. Squibb & Sons, L.L.C. $17.4105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783665163 CMS
AbbVie Inc. $13.5505/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795596027 CMS
Seagen Inc. $11.9705/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832165301 CMS
BeiGene USA, Inc. $19.0405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846697335 CMS
PFIZER INC. $14.3605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832859833 CMS
Deciphera Pharmaceuticals Inc. $18.7005/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826797111 CMS
Genentech USA, Inc. $16.8505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835920031 CMS
E.R. Squibb & Sons, L.L.C. $11.7405/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783665149 CMS
E.R. Squibb & Sons, L.L.C. $14.1405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783665151 CMS
Exelixis Inc. $11.2304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838867943 CMS
AbbVie Inc. $21.4504/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795596021 CMS
Dova Pharmaceuticals $12.8104/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849745801 CMS
Celgene Corporation $15.7104/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783733483 CMS
Myovant Sciences Inc. $23.9304/12/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834980185 CMS
Myovant Sciences Inc. $23.9304/12/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834980189 CMS
Merck Sharp & Dohme Corporation $19.6804/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848693651 CMS
E.R. Squibb & Sons, L.L.C. $12.1503/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783665139 CMS
Janssen Biotech, Inc. $18.8203/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788483065 CMS
E.R. Squibb & Sons, L.L.C. $15.8803/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783665137 CMS
Merck Sharp & Dohme Corporation $18.5503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848597129 CMS
AstraZeneca Pharmaceuticals LP $12.5703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834337879 CMS
Amgen Inc. $16.9603/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826532295 CMS
AstraZeneca Pharmaceuticals LP $15.3102/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834348179 CMS
PFIZER INC. $13.0202/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832843843 CMS
Seagen Inc. $18.1402/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832165261 CMS
Daiichi Sankyo Inc. $16.6802/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836256009 CMS
Exelixis Inc. $12.6202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838866333 CMS
Deciphera Pharmaceuticals Inc. $26.1102/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826797107 CMS
AstraZeneca Pharmaceuticals LP $11.8302/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834332595 CMS
GlaxoSmithKline, LLC. $13.8602/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802996797 CMS
Horizon Therapeutics plc $13.2701/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797185127 CMS
Merck Sharp & Dohme Corporation $18.5901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848428349 CMS
Deciphera Pharmaceuticals Inc. $18.7601/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826797103 CMS
Dova Pharmaceuticals $12.6601/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849745799 CMS
ARRAY BIOPHARMA INC $16.7601/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833183707 CMS
PFIZER INC. $11.9501/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832854599 CMS
Incyte Corporation $21.8801/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835540551 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,811.51 106
PY2020 $1,794.74 91
PY2021 $9,139.38 94
PY2022 $3,047.46 134
PY2023 $3,032.73 139
PY2024 $3,419.92 162
PY2025 $3,864.22 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $157,585.78 527
PY2024 Principal investigator $281,813.17 55
PY2023 Principal investigator $286,649.84 175
PY2022 Principal investigator $852,327.43 158
PY2021 Principal investigator $731,628.25 165
PY2020 Principal investigator $977,793.60 229
PY2019 Principal investigator $1,719,286.83 215

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

527 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664938
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664940
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664942
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664944
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664946
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664948
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664950
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664952
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664954
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664956
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664958
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664960
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664962
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664964
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664966
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664968
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664970
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664972
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664974
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664976
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664978
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664980
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664982
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664984
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664986
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664988
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664990
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664992
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664994
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664996
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664998
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665000
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665002
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665004
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665006
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665008
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665010
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665012
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665014
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665016
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665018
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665020
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665022
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665024
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665026
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665028
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665030
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665032
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665034
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665036
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665038
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665040
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665042
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665044
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665046
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665048
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665050
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665052
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665054
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665056
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665058
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665060
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665062
Principal investigator 1 Genmab U.S., Inc. $2,000.00 12/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934514
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664808
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664810
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664812
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664814
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664816
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664818
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664820
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664822
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664824
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664826
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664828
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664830
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664832
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664834
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664836
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664838
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664840
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664842
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664844
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664846
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664848
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664850
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664852
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664854
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664856
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664858
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664860
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664862
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664864
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664866
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664868
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664870
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664872
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664874
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664876
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664878
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664880
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664882
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664884
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664886
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664888
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664890
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664892
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664894
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664896
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664898
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664900
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664902
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664904
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664906
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664908
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664910
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664912
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664914
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664916
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664918
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664920
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664922
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664924
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664926
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664928
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664930
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664932
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664934
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220664936
Principal investigator 1 Genmab U.S., Inc. $500.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934542
Principal investigator 1 Genmab U.S., Inc. $2,000.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934521
Principal investigator 1 Genmab U.S., Inc. $2,000.00 10/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934565
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665680
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665682
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665684
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665686
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665688
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665690
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665692
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665694
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665696
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665698
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665700
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665702
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665704
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665706
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665708
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665710
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665712
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665714
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665716
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665718
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665720
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665722
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665724
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665726
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665728
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665730
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665732
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665734
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665736
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665738
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665740
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665742
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665744
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665746
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665748
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665750
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665752
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665754
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665756
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665758
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665760
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665762
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665764
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665766
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665768
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665770
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665772
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665774
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665776
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665778
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665780
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665782
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665784
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665786
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665788
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665790
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665792
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665794
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665796
Principal investigator 1 Genmab U.S., Inc. $2,000.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934458
Principal investigator 1 Genmab U.S., Inc. $45.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934469
Principal investigator 1 Genmab U.S., Inc. $48.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934476
Principal investigator 1 Genmab U.S., Inc. $2,000.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934487
Principal investigator 1 Genmab U.S., Inc. $58.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934496
Principal investigator 1 Genmab U.S., Inc. $140.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934500
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665560
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665562
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665564
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665566
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665568
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665570
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665572
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665574
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665576
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665578
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665580
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665582
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665584
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665586
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665588
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665590
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665592
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665594
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665596
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665598
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665600
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665602
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665604
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665606
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665608
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665610
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665612
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665614
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665616
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665618
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665620
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665622
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665624
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665626
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665628
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665630
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665632
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665634
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665636
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665638
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665640
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665642
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665644
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665646
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665648
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665650
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665652
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665654
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665656
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665658
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665660
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665662
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665664
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665666
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665668
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665670
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665672
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665674
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665676
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665678
Principal investigator 1 Genentech, Inc. $900.00 08/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651900
Principal investigator 1 Genmab U.S., Inc. $2,000.00 08/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934453
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665436
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665438
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665440
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665442
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665444
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665446
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665448
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665450
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665452
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665454
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665456
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665458
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665460
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665462
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665464
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665466
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665468
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665470
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665472
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665474
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665476
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665478
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665480
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665482
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665484
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665486
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665488
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665490
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665492
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665494
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665496
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665498
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665500
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665502
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665504
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665506
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665508
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665510
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665512
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665514
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665516
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665518
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665520
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665522
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665524
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665526
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665528
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665530
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665532
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665534
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665536
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665538
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665540
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665542
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665544
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665546
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665548
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665550
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665552
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665554
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665556
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665558
Principal investigator 1 Genentech, Inc. $1,080.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651827
Principal investigator 1 Genentech, Inc. $325.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211652339
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665336
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665338
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665340
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665342
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665344
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665346
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665348
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665350
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665352
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665354
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665356
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665358
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665360
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665362
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665364
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665366
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665368
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665370
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665372
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665374
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665376
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665378
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665380
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665382
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665384
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665386
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665388
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665390
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665392
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665394
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665396
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665398
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665400
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665402
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665404
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665406
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665408
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665410
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665412
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665414
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665416
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665418
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665420
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665422
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665424
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665426
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665428
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665430
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665432
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665434
Principal investigator 1 Genmab U.S., Inc. $1,000.00 06/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934430
Principal investigator 1 Genmab U.S., Inc. $2,000.00 06/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934426
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665208
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665210
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665212
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665214
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665216
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665218
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665220
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665222
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665224
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665226
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665228
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665230
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665232
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665234
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665236
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665238
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665240
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665242
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665244
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665246
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665248
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665250
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665252
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665254
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665256
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665258
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665260
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665262
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665264
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665266
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665268
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665270
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665272
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665274
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665276
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665278
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665280
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665282
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665284
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665286
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665288
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665290
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665292
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665294
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665296
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665298
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665300
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665302
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665304
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665306
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665308
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665310
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665312
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665314
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665316
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665318
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665320
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665322
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665324
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665326
Principal investigator 1 Boehringer Ingelheim International GmbH $975.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665328
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665330
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665332
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665334
Principal investigator 1 Genentech, Inc. $2,750.00 05/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211650895
Principal investigator 1 Genmab U.S., Inc. $2,000.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934434
Principal investigator 1 Genentech, Inc. $14,100.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651269
Principal investigator 1 Genentech, Inc. $4,050.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651327
Principal investigator 1 Genentech, Inc. $12,100.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651375
Principal investigator 1 Genentech, Inc. $4,350.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211651412
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665130
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665132
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665134
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665136
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665138
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665140
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665142
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665144
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665146
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665148
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665150
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665152
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665154
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665156
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665158
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665160
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665162
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665164
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665166
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665168
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665170
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665172
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665174
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665176
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665178
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665180
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665182
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665184
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.19 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665186
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665188
Principal investigator 1 Boehringer Ingelheim International GmbH $1,070.57 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665190
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665192
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665194
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665196
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.94 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665198
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.19 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665200
Principal investigator 1 Boehringer Ingelheim International GmbH $1,070.57 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665202
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665204
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665206
Principal investigator 1 Genmab U.S., Inc. $2,000.00 04/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934442
Principal investigator 1 SANOFI US SERVICES INC. $1,813.00 04/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst LLC
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors No dispute reported 06/30/2026 1226135999
Principal investigator 1 Genmab U.S., Inc. $1,306.25 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235934423
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665064
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665066
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665068
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665070
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665072
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665074
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665076
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665078
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665080
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665082
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665084
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665086
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665088
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665090
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665092
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665094
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665096
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665098
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665100
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665102
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665104
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665106
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665108
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665110
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665112
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665114
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665116
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665118
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665120
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665122
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665124
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665126
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute South Region Research Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220665128
Principal investigator 1 Genmab U.S., Inc. $2,000.00 03/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235933608
Principal investigator 1 Genentech, Inc. $922.50 02/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211650398
Principal investigator 1 Genmab U.S., Inc. $2,000.00 02/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235933604
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,530.00 01/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235993845
Principal investigator 1 Genmab U.S., Inc. $3,559.51 01/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235933612
Principal investigator 1 Genmab U.S., Inc. $2,000.00 01/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235933619
Principal investigator 1 Mirati Therapeutics, Inc. $22,451.60 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530604